CGEM logo

CGEM Cullinan Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$9.00
-0.01 (-0.09%)

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, …

Market Cap: $584.41Mcullinantherapeutics.com

Price

No data yet.

Social Signal Score

58
5d
—
30d
59
2 mentions
—
60d
56
7 mentions
—
90d
58
14 mentions
—
news: 14

Analyst Ratings

8 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 0Sell 0Strong Sell 0
Avg price target$34.33+281.4%
Low $27Median $35High $41
Current Consensus

Revenue

$0.00
$0.00$6.31M$12.63M$18.94M
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-3.56
$-3.85–$-3.20
7 analysts
FY2026
$-3.12
$-3.35–$-2.80
7 analysts
FY2027
$-2.15
$-3.17–$1.10
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Nadim Ahmed
Sector
Healthcare
Industry
Biotechnology
Employees
109
Beta
-0.01
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
4.09
cullinantherapeutics.com